Sermorelin vs Tesamorelin

Same active molecule, different supply chain and dramatically different pricing. Brand Egrifta from manufacturer Theratechnologies runs about $10,673 per month retail because it is priced specifically for the HIV-associated lipodystrophy market with insurance coverage. Compounded tesamorelin through legitimate 503A pharmacies for off-label anti-aging use runs around $200 per month. It is the same tesamorelin molecule produced by a compounding pharmacy under 503A rules instead of shipped from Theratechnologies. Egrifta WR launched in 2025 as a new formulation at similar brand pricing.

The 2008 withdrawal of Geref (sermorelin) was a business decision by Merck-Serono, not an FDA safety action. The pediatric GH deficiency market was small and recombinant HGH was winning, so the manufacturer discontinued production. Sermorelin remains legal to prescribe off-label through 503A compounding pharmacies because its prior FDA approval gives it an existing drug master file and grandfathered compounding status. This is why legitimate anti-aging and HRT clinics still use it in their GH optimization protocols 18+ years after the brand withdrawal.

Tesamorelin has the only published randomized controlled trial data demonstrating visceral adipose tissue reduction in humans, from its HIV lipodystrophy approval pathway. Published studies show roughly 15-18% visceral fat reduction over 26 weeks of treatment. Sermorelin has no equivalent outcomes trials. The mechanism (GHRH receptor activation, downstream IGF-1 and lipolysis) is shared, so sermorelin likely has some visceral fat effect, but the evidence base is with tesamorelin. If visceral fat is your primary goal and you want data-supported selection, tesamorelin is the pick.

Legitimate compounded tesamorelin through HRT and anti-aging clinics runs roughly $200-400 per month, which usually includes the compound, prescribing physician visits, and baseline labs (IGF-1, GH, thyroid, metabolic panel). That is dramatically cheaper than brand Egrifta at $10,673 per month retail and broadly comparable to sermorelin programs at $150-350 per month. The 503A compounding market makes these GHRH analogs accessible at realistic clinical pricing, which is why legitimate peptide programs are built around them rather than the Category-2 research peptides.

Sermorelin works via Bioidentical analog of growth hormone releasing hormone (GHRH) that stimulates natural GH. Tesamorelin works via Synthetic GHRH analog that reduces visceral adipose tissue by stimulating growth hormone. They differ in FDA approval status, efficacy data, and cost.

Sermorelin typically costs $150 - $350/mo, while Tesamorelin costs $200 - $1,500/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.

Sermorelin is not FDA-approved (Withdrawn (off-label use continues)). Tesamorelin is FDA-approved. FDA approval indicates the treatment has met rigorous safety and efficacy standards.

Common side effects of Sermorelin include Injection site reactions, Flushing, Headache. Common side effects of Tesamorelin include Injection site reactions, Arthralgia, Peripheral edema. Always consult a healthcare provider about potential side effects.

Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.